International Journal of Gynecology & Obstetrics最新文献

{"title":"Beyond clinic readings: Twenty-four hour ambulatory blood pressure monitoring profiling enhances preterm delivery risk stratification in hypertensive pregnancies.","authors":"Li Xintong, Lan Ning, Guo Yanhong, Pei Meili, Jiang Yu, Zou Yuliang","doi":"10.1002/ijgo.70515","DOIUrl":"https://doi.org/10.1002/ijgo.70515","url":null,"abstract":"<p><strong>Objective: </strong>Hypertensive disorders of pregnancy (HDP) cause significant perinatal morbidity. We developed a nomogram predicting preterm delivery risk using pre-delivery 24-h ambulatory blood pressure monitoring (ABPM) and clinical factors.</p><p><strong>Methods: </strong>HDP patients undergoing ABPM within 1 month pre-delivery were enrolled. Multivariable logistic regression identified preterm labor predictors. Nomogram performance was validated via receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Compared with dipper and non-dipper types, the reverse dipper-type on 24-h ABPM was significantly associated with higher rates of preterm labor (55, 56.1% vs. 11, 30.6% vs. 75, 46.3%, respectively; P = 0.028) and cesarean delivery (91, 92.9% vs. 28, 77.8% vs. 145, 89.5%, respectively; P = 0.044). Multivariable analysis identified pregnancy weight gain (odds ratio [OR] 0.88, 95% confidence interval [CI]: 0.83-0.93, P < 0.001), gravidity (OR 3.60, 95% CI: 1.69-7.66, P = 0.001), assisted reproductive technology use (OR 3.99, 95% CI: 1.29-12.34, P = 0.016), nighttime systolic blood pressure load (OR 1.02, 95% CI: 1.00-1.04, P = 0.026), nighttime heart rate (OR 1.06, 95% CI: 1.03-1.09, P < 0.001), urine protein (OR 3.07, 95% CI: 1.27-7.45, P = 0.013), and urine output (OR 1.01, 95% CI: 1.00-1.01, P = 0.003) as independent risk factors for preterm labor in women with HDP. These seven variables were incorporated into a nomogram prediction model. The discriminative ability of the model was assessed using a ROC curve, yielding an AUC of 0.852. The DCA indicated a favorable net benefit and clinical utility for the model.</p><p><strong>Conclusion: </strong>This validated nomogram improves preterm risk stratification in HDP using pre-delivery ABPM parameters.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the cesarean section rate in Al Elwiya maternity teaching hospital using the Robson's 10-group classification system.","authors":"Hussam Shaker, Taghreed Alhaidari","doi":"10.1002/ijgo.70519","DOIUrl":"https://doi.org/10.1002/ijgo.70519","url":null,"abstract":"<p><strong>Objective: </strong>To determine the distribution of the cesarean section (CS) rate according to the Robson's 10-group classification system (RTGCS) and identify which groups contribute most to the rising CS rate at the concerned institute.</p><p><strong>Methods: </strong>A cross-sectional single-center study was conducted between April and September 2021. Data were extracted from patients and entered into a structured template in accordance with RTGCS criteria.</p><p><strong>Results: </strong>A total of 9200 women were included, with a mean age of 28 ± 6 years. The overall CS rate was 52.8%. Groups 5, 3, and 1 were the largest groups, contributing to 37.4%, 20.5%, and 14% of all births, respectively. Group 5 contributed to 35% of the absolute CS rate, followed by group 10 (5.9%), group 1 (2.6%), and group 2 (1.7%), collectively making up 45.2% of all CSs.</p><p><strong>Conclusions: </strong>Groups 1, 5, and 10 collectively accounted for the majority of CSs at Al Elwiya Maternity Teaching Hospital, highlighting them as key drivers of the overall CS rate. Targeted analysis of these groups will inform clinical strategies to reduce unnecessary surgical interventions and improve maternal and neonatal care.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of disrespect and abuse during childbirth in the World Health Organization European region: A mixed-method study among 22 countries.","authors":"Anna Galle, Helga Berghman, Ilaria Mariani, Maria Verdecchia, Arianna Bomben, Eline Skirnisdottir Vik, Daniela Drandic, Elizabete Pumpure, Raquel Costa, Helen Elden, Céline Miani, Barbara Baranowska, Antigoni Sarantaki, Zalka Drglin, Jelena Radetic, Alina Liepinaitienė, Virginie Rozée, Alessia Abderhalden-Zellweger, Amira Cerimagic, Martina König-Bachmann, Ourania Kolokotroni, Ilana Chertok, Maryse Arendt, Stefano Delle Vedove, Ingvild Hersoug Nedberg, Magdalena Kurbanovic, Gunta Lazdane, Tiago Miguel Pinto, Karolina Lindén, Stephanie Batram-Zantvoort, Urszula Tataj-Puzyna, Dimitra Metallinou, Anja Bohinec, Jovana Ružičić, Marija Mizgaitienė, Elise de La Rochebrochard, Michael Gemperle, Imola Simon, Maria Karanikola, Barbara Tasch, Simona Fumagalli, Marzia Lazzerini","doi":"10.1002/ijgo.70516","DOIUrl":"https://doi.org/10.1002/ijgo.70516","url":null,"abstract":"<p><strong>Objective: </strong>Despite advancements in maternity quality care worldwide, mistreatment of women during childbirth persists. Currently, there is a gap of knowledge on the occurrence of disrespect and abuse during childbirth in the World Health Organization (WHO) European region.</p><p><strong>Methods: </strong>Within the IMAgiNE EURO (Improving Maternal Newborn Care in the WHO European Region During COVID-19 Pandemic) study, women 18 years and older who gave birth in healthcare facilities in the WHO European region, were invited to complete an online validated questionnaire regarding quality of maternity care. Data were collected between March 2020 and May 2023, declared as the COVID-19 pandemic. A mixed-method analysis was conducted on women's experiences of abuse, involving descriptives and multivariate logistic regression for quantitative data and thematic analysis for qualitative data.</p><p><strong>Results: </strong>Of 50 617 participants among 22 countries, 7683 (15.2%) reported experiences of abuse ranging from 6.4% in Israel to 30.7% in Bosnia-Herzegovina, with significant differences by country, age, and birth mode. Emotional, verbal, and physical abuses were reported by 10.3%, 7.3%, and 2.4%, respectively. The thematic analysis, including 737 responses, identified several shortcomings in care that women perceived as abusive, the experience associated with abuse, and the elicited emotions. Experiences of disrespect and abuse were often linked to a sequence of actions, resulting in women feeling violated and treated as an object.</p><p><strong>Conclusion: </strong>Disrespectful maternity care was common during the COVID-19 pandemic in the WHO European region. Efforts are needed to improve communication, implementation of evidence-based practices, and respect for women's rights. Constant monitoring of disrespect and abuse indicators is needed. A paradigm shift must happen, ensuring safe and respectful care for all.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing post-cesarean sepsis: Current best practice in prevention and treatment.","authors":"Amanda Lazzaro, Gauri Karandikar, Maria L Martins, Friday Saidi, David M Aronoff, Eliana Amaral, Isabelle Boucoiran, Mandakini Megh, Bo Jacobsson, Edgar Ivan Ortiz Lizcano, Deborah Money, Dharmintra Pasupathy, Edward Buga","doi":"10.1002/ijgo.70500","DOIUrl":"https://doi.org/10.1002/ijgo.70500","url":null,"abstract":"<p><p>Cesarean section is the most common surgical procedure performed worldwide. It is associated with good perinatal and maternal outcomes when indicated. The rising global cesarean birth rate has coincided with an increase in post-cesarean sepsis - specifically site infections, which have an incidence of 7% worldwide. Post-cesarean sepsis remains a serious complication that prolongs hospital stays, resulting in additional surgery and worsening maternal morbidity and mortality, and increasing healthcare costs with socioeconomic consequences. There is no global practice guide for post-cesarean sepsis, despite most maternal deaths due to sepsis occurring postpartum. Here we introduce a FIGO Committee on Infections During Pregnancy guide on prevention and treatment of post-cesarean sepsis. We encourage strategies to keep cesarean birth rates at evidence-based levels by aiming to standardize the management of labor and to increase the percentage of vaginal births after a previous cesarean. Identification of risk factors before and during the surgery is the primary step towards prevention. These measures, combined with evidence-based strategies to promote infection prevention practices, including routine prophylactic antibiotics, skin and vaginal preparation before cesarean birth, and glove change prior to skin closure, contribute towards reducing maternal morbidity and mortality.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevating and empowering reproductive futures: Pediatric and adolescent gynecology's specialized care across the globe.","authors":"Nichole A Tyson, Méabh Ní Bhuinneáin, Hema Divakar, Lauren Mauger, Judith Simms Cendan, Marisa Labovsky","doi":"10.1002/ijgo.70499","DOIUrl":"https://doi.org/10.1002/ijgo.70499","url":null,"abstract":"<p><p>Pediatric and adolescent gynecology (PAG) is an expanding subspecialty of obstetrics and gynecology that addresses the reproductive health needs of girls and young women worldwide. In regions with limited subspecialist healthcare providers, general obstetricians, gynecologists, and nurse-midwives, frontline healthcare providers provide essential PAG services. In this article, we examine the multifaceted role of PAG, encompassing preventive care counseling, clinical care, surgical expertise, endocrine management, genetic counseling, and advocacy, while offering resources for generalists. PAG specialists deliver age-tailored care for conditions such as menstrual disorders, Müllerian anomalies, and endometriosis, while managing complex cases involving developmental delays, cancer, and differences in sex development. They also support adolescents during pregnancy, offering prenatal care, postnatal contraception counseling, safe abortion care, and interventions aimed at reducing sequential adolescent births. PAG providers promote health and wellness in their care models through opportunistic prevention measures and screening. Globally, PAG training varies. Formal fellowships and integrated programs exist around the world. Organizations such as the North American Society for Pediatric and Adolescent Gynecology (NASPAG), the International Federation of Pediatric and Adolescent Gynecology (FIGIJ), the Asia Oceania Society of Pediatric and Adolescent Gynecology (AOSPAG), the Latin American Association of Pediatric and Adolescent Gynecology (ALOGIA), the European Association of Pediatric and Adolescent Gynecology (EURAPAG), and national associations drive education, research, capacity building, and policy advocacy, addressing disparities through initiatives including human papillomavirus vaccination and comprehensive sex education.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global determinants of gynecologic cancer incidence and mortality: A cluster-based analysis with predictive insights","authors":"Mauricio A. Cuello,&nbsp;Fernán Gomez-Valenzuela,&nbsp;Ignacio Wichmann,&nbsp;Alexander B. Olawaiye","doi":"10.1002/ijgo.70279","DOIUrl":"10.1002/ijgo.70279","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Gynecologic cancers, including cervical, ovarian, and endometrial cancers, remain a significant global health challenge. In 2022, 9 175 141 new cancer cases were reported among females, with 1 473 427 (16.1%) attributed to gynecologic cancers, reflecting an incidence rate of 30.4 per 100 000. These cancers were responsible for 680 372 deaths, representing 15.9% of total female cancer mortality at a rate of 17.3 per 100 000. Identifying the drivers of incidence and mortality is critical for addressing disparities and advancing the United Nations Sustainable Development Goals (SDGs), particularly those targeting health equity and gender equality.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To identify and analyze the socioeconomic, healthcare, lifestyle, and environmental determinants driving gynecologic cancer incidence and mortality globally. The study leveraged a cluster-based approach across 68 countries, representing 34.9% of global nations and spanning diverse geographic and economic contexts.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Eighty-seven variables were analyzed using Principal Component Analysis (PCA), consolidating them into 17 key components that explained 74.4% of the total variance. These components informed a hierarchical clustering process that grouped countries into four profiles based on shared characteristics. Cluster-specific backward regression models examined the influence of these components on standardized incidence and mortality rates (Adjusted Rate Standardized, ARS). Monte Carlo simulations validated projections, providing robust insights into disparities.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study revealed significant cluster-specific variability in factors influencing gynecologic cancer outcomes. Cluster 1 excelled in lifestyle-driven cancer prevention, whereas systemic barriers in Cluster 4 necessitate urgent healthcare investment and policy reform. Intermediate clusters exhibited variability influenced by social stability, environmental health, and healthcare infrastructure. The analysis underscored disparities in key predictors such as HPV vaccination coverage, healthcare expenditure, public health policies, and access to preventive services.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study highlights the importance of tailored, cluster-specific strategies to reduce disparities in gynecologic cancer outcomes. Interventions should prioritize ","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"171 S1","pages":"147-165"},"PeriodicalIF":2.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.70279","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategic approaches for global cervical cancer elimination: An update review and call for national action","authors":"Sarikapan Wilailak,&nbsp;Malika Kengsakul,&nbsp;Sean Kehoe","doi":"10.1002/ijgo.70276","DOIUrl":"10.1002/ijgo.70276","url":null,"abstract":"<p>Cervical cancer remains a major health burden, particularly in low- and middle-income countries, despite being one of the most preventable cancers. WHO's 90–70–90 targets aim to eliminate cervical cancer globally by 2030. These targets include 90% of girls fully vaccinated with the HPV vaccine by the age of 15 years, 70% of women screened using a high-performance test by the age of 35 years and again by 45 years, and 90% of women with cervical disease receiving appropriate treatment. Achieving these goals requires coordinated national efforts to strengthen health systems, ensure equitable access to care, and integrate cervical cancer control into broader health policies. This review outlines key strategic approaches, including the transition from conventional screening methods to HPV-based screening, the adoption of innovative triage techniques, the implementation of single-dose HPV vaccination, and the integration of primary treatment with palliative care. The strategy places strong emphasis on addressing health inequities, enhancing monitoring systems, and fostering partnerships between governments, non-governmental organizations, and the private sector. With concerted global and national action, the elimination of cervical cancer is not only a possibility but an imminent reality.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"171 S1","pages":"120-128"},"PeriodicalIF":2.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.70276","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global disparities in gynecologic cancer outcomes: A call for action","authors":"Kenneth Ruzindana,&nbsp;Rose I. Anorlu","doi":"10.1002/ijgo.70278","DOIUrl":"10.1002/ijgo.70278","url":null,"abstract":"<p>Gynecologic cancers pose a substantial global health challenge, disproportionately affecting women in low- and middle-income countries (LMICs). Although high-income countries (HICs) have witnessed advancements in prevention, early detection, and treatment, LMICs continue to experience elevated incidence and mortality rates, coupled with diminished survival outcomes. In 2022, these cancers accounted for approximately 1.4 million new cases and over 600 000 deaths worldwide, concentrated primarily in LMICs. This disparity stems from a confluence of systemic factors, including limited access to health care, absent or inadequate cervical cancer screening programs, underdeveloped healthcare infrastructure, and socioeconomic barriers such as poverty and lack of health insurance. Furthermore, shortages of trained specialists, advanced diagnostic tools, and effective treatment modalities hinder care delivery in resource-constrained settings. This paper delves into the root causes of these disparities, exploring the systemic and structural obstacles impeding equitable gynecologic oncology care in LMICs. Evidence-based recommendations will focus on expanding access to preventative measures like HPV vaccination and cervical cancer screening, enhancing timely diagnosis and treatment, and bolstering healthcare systems to address workforce and infrastructure deficits. Achieving equitable outcomes requires concerted global efforts to bridge resource gaps, prioritize health system reforms, and cultivate partnerships between HICs and LMICs for expertise and resource sharing. Ultimately, addressing these disparities is essential to ensure that all women, irrespective of geographic location or socioeconomic status, can access quality care, thereby mitigating the global burden of gynecologic cancers and improving survival.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"171 S1","pages":"210-220"},"PeriodicalIF":2.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.70278","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives","authors":"Nozomu Yanaihara,&nbsp;Ka Yu Tse,&nbsp;Sung Jong Lee,&nbsp;Ji Geun Yoo,&nbsp;Sarikapan Wilailak","doi":"10.1002/ijgo.70280","DOIUrl":"10.1002/ijgo.70280","url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by leveraging the immune system's capacity to fight gynecologic cancer. This review summarizes the current status and future perspectives of ICIs in the treatment of cervical, endometrial, and ovarian cancers and rare tumors. ICIs have demonstrated significant efficacy in tumors with high tumor mutational burden and immune markers such as PD-L1 expression and microsatellite instability. In cervical cancer, the integration of ICIs has shown promise at various stages of treatment, including advanced and recurrent settings. In endometrial cancer, molecular classification has facilitated targeted immunotherapy strategies, with notable success in mismatch repair-deficient (dMMR) tumors. However, challenges remain in the treatment of microsatellite stable endometrial and epithelial ovarian cancers due to their relatively low immunogenicity. Combination therapies, including ICIs with angiogenesis inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, or chemotherapy, are being actively investigated to improve response rates. Several phase II and case series showed promising response to ICIs in vulvar/vaginal cancer and gestational trophoblastic neoplasia, though the efficacy in genital tract melanoma is still unclear. Despite these advances, the management of immune-related adverse events and the identification of reliable biomarkers for patient selection remain critical. ICIs are poised to redefine the therapeutic landscape of gynecologic oncology, offering hope for improved outcomes and personalized treatment strategies.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"171 S1","pages":"166-188"},"PeriodicalIF":2.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.70280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","authors":"Malte Renz,&nbsp;Michael Friedlander,&nbsp;Jonathan S. Berek","doi":"10.1002/ijgo.70282","DOIUrl":"10.1002/ijgo.70282","url":null,"abstract":"<p>In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension) and IIIA1(ii) (metastasis &gt;10 mm in greatest dimension). Stage IIIA2 is now “microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node” metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, including the treatment of ovarian germ cell and stromal malignancies.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"171 S1","pages":"6-35"},"PeriodicalIF":2.4,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.70282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}